US8870802084 - Common Stock
TIMBER PHARMACEUTICALS INC
NYSEARCA:TMBR (11/28/2023, 7:04:00 PM)
Premarket: 0.3532 +0.01 (+3.09%)0.3426
+0 (+0.74%)
Timber Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The company is headquartered in Warren, New Jersey and currently employs 9 full-time employees. The company went IPO on 2015-06-11. The firm is focused on the development and commercialization of treatments for orphan dermatologic diseases. The firm is also focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), including X-linked recessive CI (XLRI) and autosomal recessive CI (ARCI) and other sclerotic skin diseases. Its lead late-stage program is TMB-001. TMB-003 is its earliest stage program. TMB-001 is a topical formulation of isotretinoin using its patented IPEG delivery system, completed its Phase IIb clinical trial for the treatment of moderate to severe subtypes of CI. The earliest stage product in its pipeline is TMB-003, a formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist. The company is in preclinical development as a locally applied formulation for the treatment of sclerotic skin diseases.
TIMBER PHARMACEUTICALS INC
3 Mountainview Road, Suite 100
WARREN NEW JERSEY 07920
P: 19176973130.0
CEO: John Koconis
Employees: 9
Website: https://www.timberpharma.com/
Timber Pharmaceuticals (TMBR) announces immediate suspension of common stock trading on NYSE America, expected to continue trading on OTC Market as TMBRQ.
WARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. (
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical...
Timber Pharmaceuticals (TMBR) reportedly filed for Chapter 11 bankruptcy protection Friday afternoon after shareholders again refused to approve a planned merge
Timber Pharmaceuticals (TMBR) shares fall ahead of a crucial shareholder meeting on Friday regarding its proposed merger with LEO Pharma. Read more here.
Here you can normally see the latest stock twits on TMBR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: